ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zilucoplan

Also written as “Zilucoplan”, “zilucoplan (RA101495)” and “Zilucoplan (RA101495)”.

Its studies are mostly in Myasthenia Gravis · Hemoglobinuria, Paroxysmal · Muscular Diseases · COVID-19, led by 2 companies.

Drug pageZilucoplan: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 2, 201914 company-led studies, 3 open or runningNext primary completion: Mar 23, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCBits history only133 open or runningphase 3since Oct 2, 2019Jan 20, 2017Mar 23, 2027phase 1 · NCT06961747
Amgen10 open or runningphase 3since Oct 14, 2020Oct 14, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named zilucoplanINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Oct 14, 2020First study: phase 3 study in COVID-19First studyNCT04590586 · 515 enrolled · United States, Argentina, Brazil and more

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

The one study Amgen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04590586COVID-19 · United States, Argentina, Brazil and more3CompletedAug 3, 2021515

How it is read

Names in the registry

  • “Zilucoplan”, 6 entries
  • “zilucoplan (RA101495)”, 4 entries
  • “Zilucoplan (RA101495)”, 3 entries
  • “zilucoplan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.